このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Cue Biopharma マネジメント
マネジメント 基準チェック /24
Cue Biopharma'sの CEO はDan Passeriで、 Aug2016年に任命され、 の在任期間は 7.83年です。 の年間総報酬は$ 3.02Mで、 20.1%給与と79.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.28%を直接所有しており、その価値は$ 181.68K 。経営陣と取締役会の平均在任期間はそれぞれ6.1年と6年です。
主要情報
Dan Passeri
最高経営責任者
US$3.0m
報酬総額
| CEO給与比率 | 20.1% |
| CEO在任期間 | 7.8yrs |
| CEOの所有権 | 0.3% |
| 経営陣の平均在職期間 | 6.1yrs |
| 取締役会の平均在任期間 | 6yrs |
経営陣の近況
Recent updates
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money
Apr 16
Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?
Dec 30Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?
Aug 11Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug
Oct 04Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt
Sep 23News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat
Aug 26Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates
Aug 10Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%
May 18Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 12Cue Biopharma: A First Assessment
May 11Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Mar 19Cue Biopharma: Too Long To Arrive At Topline Trial Data
Feb 23We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth
Nov 04Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer
Jun 10Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth
Jun 07Cue Biopharma's CUE-101 shows encouraging action in HPV+ head and neck cancer patients
May 10How Many Cue Biopharma, Inc. (NASDAQ:CUE) Shares Did Insiders Buy, In The Last Year?
Mar 21We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Feb 22Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders?
Jan 27
Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022
Jan 07Reflecting on Cue Biopharma's (NASDAQ:CUE) Share Price Returns Over The Last Year
Dec 25Independent Director Aaron Fletcher Just Bought 3.9% More Shares In Cue Biopharma, Inc. (NASDAQ:CUE)
Nov 29We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Nov 24CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$50m |
| Dec 31 2023 | US$3m | US$605k | -US$51m |
| Sep 30 2023 | n/a | n/a | -US$52m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$52m |
| Dec 31 2022 | US$1m | US$748k | -US$53m |
| Sep 30 2022 | n/a | n/a | -US$47m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$46m |
| Dec 31 2021 | US$2m | US$531k | -US$44m |
| Sep 30 2021 | n/a | n/a | -US$47m |
| Jun 30 2021 | n/a | n/a | -US$44m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$6m | US$501k | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$43m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$1m | US$395k | -US$37m |
| Sep 30 2019 | n/a | n/a | -US$39m |
| Jun 30 2019 | n/a | n/a | -US$45m |
| Mar 31 2019 | n/a | n/a | -US$43m |
| Dec 31 2018 | US$834k | US$345k | -US$39m |
| Sep 30 2018 | n/a | n/a | -US$38m |
| Jun 30 2018 | n/a | n/a | -US$30m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$410k | US$325k | -US$23m |
報酬と市場: Danの 総報酬 ($USD 3.02M ) は、 US市場 ($USD 678.50K ) の同規模の企業の平均を上回っています。
報酬と収益: Danの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Dan Passeri (63 yo)
7.8yrs
在職期間
US$3,015,480
報酬
Mr. Daniel R. Passeri, also known as Dan, MSc. J.D. has been the Chief Executive Officer and Director of Cue Biopharma, Inc. since August 2016 and also served as its President since August 2016 until Octob...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 7.8yrs | US$3.02m | 0.28% $ 194.5k | |
| President & Chief Scientific Officer | 6.1yrs | US$1.21m | 0.28% $ 196.0k | |
| Chief Financial Officer | 6.1yrs | US$1.16m | 0.029% $ 20.7k | |
| Co-Founder | no data | US$316.63k | データなし | |
| Co-Founder & Senior Advisor | no data | US$316.63k | データなし | |
| Co-Founder and Chairman of Scientific & Clinical Advisory Board | no data | データなし | データなし | |
| Senior VP | 6.5yrs | US$625.51k | データなし | |
| Chief Medical Officer | 3.3yrs | データなし | 0.019% $ 13.3k |
6.1yrs
平均在職期間
54.5yo
平均年齢
経験豊富な経営陣: CUEの経営陣は経験豊富で経験豊富です（平均在職期間は6.1年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 7.8yrs | US$3.02m | 0.28% $ 194.5k | |
| Co-Founder and Chairman of Scientific & Clinical Advisory Board | 9.4yrs | データなし | データなし | |
| Independent Director | 6yrs | US$76.31k | 0% $ 0 | |
| Independent Chairman of the Board | 5.9yrs | US$106.27k | 0.058% $ 40.5k | |
| Independent Director | 8.3yrs | US$144.18k | 0.00073% $ 513.1 | |
| Member of Scientific & Clinical Advisory Board | no data | データなし | データなし | |
| Member of Scientific & Clinical Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | 1.3yrs | データなし | データなし | |
| Clinical Advisor | 1.4yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 3.3yrs | データなし | データなし | |
| Member of Scientific & Clinical Advisory Board | 7.3yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 3.3yrs | データなし | データなし |
6.0yrs
平均在職期間
67.5yo
平均年齢
経験豊富なボード: CUEの 取締役会 は 経験豊富 であると考えられます ( 6年の平均在任期間)。